MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare study: comprehensive eye exams can help re-engage patients into care for certain chronic conditions, with the potential to help improve health and reduce costs.
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida reports positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis
TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ:4573) R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology, Graduate Scho…
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of pre-clinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal PLOS ONE. The published article, “Visual Cycle Modulation as an Approach Towa
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today reported financial results for the three-month period ended March 31, 2015. Company Highlights Successfully implanted 19 Argus® II systems in the first quarter of 2015, the highest number for any quarter to date; Net revenue increased 159% to $1.7 millio
LONDON–(BUSINESS WIRE)–Technavio has published a new report on the global capsule endoscope market, which is expected to grow at a CAGR of 11% from 2015-2019.
PORTLAND, Ore.–(BUSINESS WIRE)–Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, announced today that it has entered into a multi-year agreement with global healthcare supplier Perrigo Company plc to promote the ilast® range of products for eyelid hygiene in the United States. “The ilast® brand is an integral part of our portfolio of branded products,” said Patrick Witham, President and CEO of Paragon BioTeck, Inc. “By expanding our promotional efforts to incl
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced tod…
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the UBS Global Healthcare Conference in New York City on Monday, May 18, 2015.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jjzjdp/north_american) has announced the addition of the “North American Ophthalmology Surgery Devices Market by Types, by End-users – Forecast to 2019” report to…
LONDON–(BUSINESS WIRE)–ISG has commenced work on a £4.5 million project to create a state-of-the-art eye hospital in London’s renowned Marylebone medical district, for high-end ophthalmic specialist Optegra. The scheme involves the conversion of two period properties in Queen Anne Street into an advanced facility for the treatment of a comprehensive range of eye conditions. Retaining the attractive Edwardian and Victorian façades of the two buildings, ISG will rationalise and unify space and
SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015. “FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease,” said Thomas B. Neff, chief executive officer of FibroGen. “Patient enrollment in the seven Phase 3 studies re
TOKYO–(BUSINESS WIRE)–HOYA Corporation (TOKYO: 7741) today announced financial results for the fourth quarter and full-year ended March 31, 2015. During the quarter, revenues increased by 10.6% to 127,440 million yen compared with the same period las…
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City. “Dr. Lanza’s pioneering research is providing hope for millions of people who may one day benefit from breakthrough c
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this year’s annual meeting of the American Association for Cancer Resea
DUBLIN–(BUSINESS WIRE)–PRESBIA TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals Features Key Opinion Leaders in Ophthalmology and Optometry in Analyst and Investor Day Event on May 19